Seelos Therapeutics PE Ratio 2010-2022 | SEEL
Current and historical p/e ratio for Seelos Therapeutics (SEEL) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Seelos Therapeutics PE ratio as of May 27, 2022 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Seelos Therapeutics PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2022-05-27 |
0.62 |
|
0.00 |
| 2022-03-31 |
0.84 |
$-0.34 |
0.00 |
| 2021-12-31 |
1.63 |
$-0.49 |
0.00 |
| 2021-09-30 |
2.41 |
$-0.62 |
0.00 |
| 2021-06-30 |
2.64 |
$-0.60 |
0.00 |
| 2021-03-31 |
4.99 |
$-0.58 |
0.00 |
| 2020-12-31 |
1.58 |
$-0.44 |
0.00 |
| 2020-09-30 |
0.94 |
$-0.58 |
0.00 |
| 2020-06-30 |
1.01 |
$-0.62 |
0.00 |
| 2020-03-31 |
0.49 |
$-0.63 |
0.00 |
| 2019-12-31 |
1.34 |
$-4.47 |
0.00 |
| 2019-09-30 |
0.92 |
$-4.20 |
0.00 |
| 2019-06-30 |
2.19 |
$-7.67 |
0.00 |
| 2019-03-31 |
3.36 |
$-10.59 |
0.00 |
| 2018-12-31 |
5.76 |
$-10.81 |
0.00 |
| 2018-09-30 |
9.30 |
$-15.62 |
0.00 |
| 2018-06-30 |
11.70 |
$-20.72 |
0.00 |
| 2018-03-31 |
12.18 |
$-21.62 |
0.00 |
| 2017-12-31 |
55.20 |
$13.81 |
4.00 |
| 2017-09-30 |
51.30 |
$17.42 |
2.95 |
| 2017-06-30 |
33.90 |
$20.42 |
1.66 |
| 2017-03-31 |
63.30 |
$9.31 |
6.80 |
| 2016-12-31 |
39.00 |
$-48.95 |
0.00 |
| 2016-09-30 |
101.49 |
$-62.76 |
0.00 |
| 2016-06-30 |
119.85 |
$-87.09 |
0.00 |
| 2016-03-31 |
174.30 |
$-102.10 |
0.00 |
| 2015-12-31 |
297.00 |
$-114.11 |
0.00 |
| 2015-09-30 |
438.00 |
$-219.22 |
0.00 |
| 2015-06-30 |
513.00 |
$-213.21 |
0.00 |
| 2015-03-31 |
561.00 |
$-168.17 |
0.00 |
| 2014-12-31 |
300.00 |
$-156.16 |
0.00 |
| 2014-09-30 |
453.00 |
$-48.05 |
0.00 |
| 2014-06-30 |
675.00 |
$-48.05 |
0.00 |
| 2014-03-31 |
645.00 |
$-99.10 |
0.00 |
| 2013-12-31 |
795.00 |
$-159.16 |
0.00 |
| 2013-09-30 |
627.00 |
$-345.35 |
0.00 |
| 2013-06-30 |
705.00 |
$-348.35 |
0.00 |
| 2013-03-31 |
804.00 |
$-312.31 |
0.00 |
| 2012-12-31 |
597.00 |
$-285.29 |
0.00 |
| 2012-09-30 |
978.00 |
$-153.15 |
0.00 |
| 2012-06-30 |
1023.00 |
$-159.16 |
0.00 |
| 2012-03-31 |
846.00 |
$-276.28 |
0.00 |
| 2011-12-31 |
1548.00 |
$-270.27 |
0.00 |
| 2011-09-30 |
1074.00 |
$-426.43 |
0.00 |
| 2011-06-30 |
1437.00 |
$-453.45 |
0.00 |
| 2011-03-31 |
1257.00 |
$-477.48 |
0.00 |
| 2010-12-31 |
1041.00 |
$-783.60 |
0.00 |
| 2010-09-30 |
519.00 |
$-663.48 |
0.00 |
| 2010-06-30 |
630.00 |
$-648.45 |
0.00 |
| 2010-03-31 |
2070.45 |
$-597.35 |
0.00 |
| 2009-12-31 |
1282.50 |
$-192.15 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.065B |
$0.000B |
|
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
|
